Publications by Professor James Allan - ePrints

Browsing publications by Professor James Allan.

Newcastle Authors	Title	Year
Dr Sarah Fordham Dr Wei-Yu Lin Dr Helen Blair Dr Claire Elstob Dr Hayden Bell et al.	Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia	2023
Professor James Allan	Inherited cancer predisposing mutations in patients with therapy-related myeloid neoplasms	2023
Dr Jose Luis Marin-Rubio Dr Maria Duenas Fadic Dr Tiaan Heunis Dr Abeer Dannoura Dr Joe Inns et al.	A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia	2022
Dr Wei-yu Lin Dr Sarah Fordham Dr Nicola Sunter Dr Claire Elstob Dr Yaobo Xu et al.	Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (Nature Communications, (2021), 12, 1, (6233), 10.1038/s41467-021-26551-x)	2022
Dr Ricky Tirtakusuma Dr Katarzyna Szoltysek Professor Vasily Grinev Dr Sirintra Nakjang Dr Daniel Williamson et al.	Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia	2022
Dr Deepali Pal Dr Helen Blair Sean Hockney Dr Melanie Beckett Mankaran Singh et al.	hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia	2022
Professor James Allan	Genome-Wide Association Analyses Identify Variants in IRF4 Associated With Acute Myeloid Leukemia and Myelodysplastic Syndrome Susceptibility	2021
Dr Wei-Yu Lin Dr Sarah Fordham Dr Nicola Sunter Dr Claire Elstob Dr Thahira Rahman et al.	Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia	2021
Dr Wei-Yu Lin Dr Sarah Fordham Dr Nicola Sunter Dr Claire Elstob Dr Yaobo Xu et al.	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia	2021
Professor James Allan Professor Christine Harrison FRCPath FMedSci Professor Anthony Moorman	Author correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia	2019
Dr Nicola Sunter Professor Graham Jackson Professor James Allan	Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology	2019
Professor James Allan	Genetic susceptibility to breast cancer in lymphoma survivors	2019
Professor James Allan Professor Anthony Moorman	Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk	2019
Professor James Allan	Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics	2019
Professor James Allan	Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9	2019
Professor James Allan Professor Christine Harrison FRCPath FMedSci Professor Anthony Moorman	Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia	2018
Dr Sarah Fordham Dr Helen Blair Dr Claire Elstob Professor Ruth Plummer Dr Yvette Drew et al.	Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase	2018
Dr Lynsey McKenzie Hasan Issa Sandeep Potluri Dr Helen Blair Asmida Isa et al.	The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation	2018
Professor Anthony Moorman Professor Julie Irving Professor James Allan Professor Christine Harrison FRCPath FMedSci	A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1	2017
Dr Aiste McCormick Gavin Cuthbert Dr Rachel O'Donnell Dr Brian Wilson Huw Thomas et al.	Functional characterisation of a novel ovarian cancer cell line, NUOC-1	2017
Dr Nicola Sunter Dr Andrew Hall Dr Tryfonia Mainou-Fowler Professor Graham Jackson Dr Helen Marr et al.	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia	2017
Dr Nicola Sunter Professor Graham Jackson Dr Thahira Rahman Professor James Allan	Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci	2017
Dr David Jamieson Dr Nicola Sunter Sara Muro Dr Nicola Cresti Julieann Sludden et al.	Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide	2017
Professor Graham Jackson Professor James Allan	Telomere length is a critical determinant for survival in multiple myeloma	2017
Professor James Allan	Genetic Predisposition to Chronic Lymphocytic Leukemia Is Mediated by a BMF Super-Enhancer Polymorphism	2016
Dr Victoria Forster Mohammed Nahari Dr Natalia Martinez Soria Amy Bradburn Dr Sarah Fordham et al.	The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype	2016
Professor James Allan	Whole-exome Sequence Analysis Implicates Rare Il17REL Variants in Familial and Sporadic Inflammatory Bowel Disease	2016
Dr Mark Wade Dr Nicola Sunter Dr Sarah Fordham Anna Long Dino Mašić et al.	c-MYC is a radiosensitive locus in human breast cells	2015
Professor James Allan	Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis	2015
Fiona Middleton Dr Miranda Patterson Dr Claire Elstob Dr Sarah Fordham Dr Ashleigh Herriott et al.	Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition	2015
Dr Nicola Sunter Dr Helen Marr Dr Andrew Hall Dr Tryfonia Mainou-Fowler Professor Graham Jackson et al.	Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk	2015
Dr Sarah Fordham Mike Cole Professor Julie Irving Professor James Allan	Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia	2015
Professor Julie Irving Elizabeth Matheson Helen Blair Marian Case Isabella Swidenbank et al.	Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124(23):3420-3430	2015
Dr Helen Marr Dr Luke Gaughan Dr Susan Tudhope Professor James Allan	Regulation of CD38 in IRF4 in Chronic Lymphocytic Leukaemia	2015
Professor James Allan	Second cancers	2015
Professor Anthony Moorman Professor Julie Irving Professor James Allan Professor Christine Harrison FRCPath FMedSci	The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A	2015
Dr Victoria Forster Mohammed Nahari Dr Natalia Martinez Soria Amy Bradburn Hesta McNeill et al.	The Leukemia-Associated RUNX1/ETO Oncoprotein Confers a Mutator Phenotype	2015
Dr Nicola Sunter Dr Andrew Hall Dr Tryfonia Mainou-Fowler Professor Graham Jackson Professor James Allan et al.	A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia	2014
Dr Sarah Fordham Mike Cole Professor Julie Irving Professor James Allan	Cytarabine leaves a mutational fingerprint in relapsing leukemia	2014
Professor Julie Irving Elizabeth Matheson Dr Helen Blair Marian Case Isabella Swidenbank et al.	Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition	2014
Professor James Allan	Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy	2014
Professor James Allan	Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease	2014
Professor James Allan	Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors	2013
Professor Graham Jackson Professor Julie Irving Professor James Allan	Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk	2013
Dr Sarah Fordham Dr Helen Marr Professor James Allan	Searching for clarity in therapy-related myelodysplastic syndrome/acute myeloid leukemia prognostication	2013
Professor Julie Irving Professor James Allan	Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype	2013
Dr Sarah Fordham Dr Victoria Forster Professor Graham Jackson Dr Simon Bomken Professor James Allan et al.	A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia	2012
Dr Andrea Beyerle Professor Olaf Heidenreich Professor James Allan	AML1/ETO Confers a Mutator Phenotype in AML	2012
Professor Julie Irving Professor James Allan	Common genetic variation contributes significantly to the risk of childhood B-cell precursor acute lymphoblastic leukemia	2012
Professor James Allan	Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy	2012
Dr Victoria Forster Dr Andrea Beyerle Professor Olaf Heidenreich Professor James Allan	AML1/ETO Confers a Mutator Phenotype In Acute Myeloid Leukemia Associated with Downregulation of the Base-Excision-Repair Gene OGG1	2011
Professor Julie Irving Professor James Allan	DNA mismatch repair status affects cellular response to Ara-C and other anti-leukemic nucleoside analogs	2011
Dr Victoria Forster Amy Bradburn Professor James Allan Professor Olaf Heidenreich	The Angiogenic Factor Angiopoietin-1 Is Regulated by the Acute Myeloid Leukemia Fusion Protein AML1/ETO	2011
Professor Graham Jackson Dr Simon Bomken Professor James Allan	A Functional Polymorphism In the CD95 Cell Death Receptor Associated with Prognosis In Acute Promyelocytic Leukemia	2010
Dr Nicola Sunter Professor Graham Jackson Dr Simon Bomken Professor James Allan	A Functional Polymorphism In the CD95 Cell Death Receptor Associated with Prognosis In Acute Promyelocytic Leukemia	2010
Professor Graham Jackson Dr Nicola Sunter Dr Andrew Hall Professor Julie Irving Professor James Allan et al.	A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma	2010
Professor Julie Irving Professor James Allan	Cellular Response to Cytarabine Is Modulated by the DNA Mismatch Repair Pathway: Implications for Treatment of Acute Myeloid Leukemia	2010
Dr Sarah Fordham Emeritus Professor Keith Scott Professor Julie Irving Professor James Allan	Cellular Response to Cytarabine is Modulated by the DNA Mismatch Repair Pathway: Implications for Treatment of Acute Myeloid Leukemia	2010
Dr Nicola Sunter Dr Andrew Hall Dr Tryfonia Mainou-Fowler Professor Graham Jackson Professor James Allan et al.	Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk	2010
Professor James Allan	Genetic variation in the folate metabolic pathway and risk of childhood leukemia	2010
Professor Julie Irving Professor James Allan	Genome-wide homozygosity signatures and childhood acute lymphoblastic leukemia risk	2010
Dr Rachel Crossland Professor Stephen Proctor Professor James Allan	Mature MicroRNAs Mir 18, 19a, 19b, 17 5p and 92 of the Mir 17 92 Cluster Predict for Treatment Free Survival In Patients with Chronic Lymphocytic Leukaemia	2010
Dr Rachel Crossland Professor Stephen Proctor Professor James Allan Dr Tryfonia Mainou-Fowler	Mature MicroRNAs Mir-18,-19a,-19b,-17-5p and-92 of the Mir-17-92 Cluster Predict for Treatment Free Survival In Patients with Chronic Lymphocytic Leukaemia	2010
Professor James Allan	Melanocortin 1 receptor (MC1R), pigmentary characteristics and sun exposure: findings from a case-control study of diffuse large B-cell and follicular lymphoma	2010
Professor Julie Irving Professor James Allan	MHC variation and risk of childhood B-cell precursor acute lymphoblastic leukaemia	2010
Professor James Allan	Non-Homologous End-Joining Gene Profiling Reveals Distinct Expression Patterns Associated with Lymphoma and Multiple Myeloma	2010
Professor James Allan	Testicular Cancer Survivorship: Research Strategies and Recommendations	2010
Dr Victoria Forster Professor James Allan Professor Olaf Heidenreich	The t(8,21) Fusion Protein AML1/ETO Promotes Susceptibility to Mutation In Acute Myeloid Leukemia	2010
Dr Victoria Forster Professor James Allan Professor Olaf Heidenreich	The t(8;21) Fusion Protein AML1/ETO Promotes Susceptibility to Mutation In Acute Myeloid Leukemia	2010
Professor James Allan Dr Nicola Sunter Dr Andrew Hall Dr Christopher Bacon Jonathan Pointon et al.	Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia	2010
Professor Julie Irving Professor James Allan Professor Anthony Moorman Professor Christine Harrison FRCPath FMedSci	Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk	2010
Professor James Allan	[Meeting Abstract] DNA repair dysfunction and genomic instability in therapy-related malignancy	2009
Professor James Allan	Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial	2009
Professor James Allan	Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility	2009
Professor Julie Irving Professor James Allan	Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia	2009
Professor James Allan	Polymorphisms in the nucleotide excision repair gene ERCC2/XPD and risk of non-Hodgkin lymphoma	2009
Professor James Allan	MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility	2008
Professor James Allan Dr Nicola Sunter Dr Andrew Hall Dr Tryfonia Mainou-Fowler Professor Graham Jackson et al.	A Common Genetic Variant in the 3'UTR of IRF4/MUM1 Associates with Risk of Disease and Poor Prognosis in Chronic Lymphocytic Leukaemia	2008
Professor James Allan	A Genome-Wide Analysis to Identify Novel Susceptibility Loci for Therapy-Related Acute Myeloid Leukemia	2008
Dr Nicola Sunter Dr Andrew Hall Dr Tryfonia Mainou-Fowler Professor Graham Jackson Professor James Allan et al.	A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia	2008
Professor James Allan	Genetic susceptibility to radiogenic cancer in humans	2008
Professor James Allan	Genetic variation in genes expressed in the germinal center and risk of B cell lymphoma among Caucasians	2008
Professor James Allan	Influence of DNA repair gene polymorphisms on the initial repair of MMS-induced DNA damage in human lymphocytes as measured by the alkaline comet assay	2008
Professor James Allan	MLH1 -93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer	2008
Professor Graham Jackson Professor James Allan	Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma	2008
Professor James Allan	Risk of Leukemia Among Survivors of Testicular Cancer: A Population-based Study of 42,722 Patients	2008
Professor James Allan	The Genetics of Cancer Survivorship	2008
Professor James Allan	A common genetic variant in XPD associates with risk of 5q- and 7q-deleted acute myeloid leukemia	2007
Professor James Allan	Deregulation of homologous recombination DNA repair in alkylating agent-treatedstem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia	2006
Professor James Allan	Mechanisms of therapy-related carcinogenesis	2005
Professor James Allan	Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy	2004
Professor James Allan	An Intron Splice Acceptor Polymorphism in hMSH2 and Risk of Leukemia after Treatment with Chemotherapeutic Alkylating Agents	2003
Professor James Allan	Genetic alterations in bronchial mucosa and plasma DNA from individuals at high risk of lung cancer	2001
Professor James Allan Professor Anthony Moorman	Polymorphism in glutathione S-transferase PI is associated with susceptibility to chemotherapy-induced leukaemia	2001